These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35295080)

  • 1. Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19.
    Garcia-Vidal C; Puerta-Alcalde P; Mateu A; Cuesta-Chasco G; Meira F; Lopera C; Monzo P; Santos-Bravo M; Duenas G; Chumbita M; Garcia-Pouton N; Gaya A; Bodro M; Herrera S; Mosquera M; Fernandez-Aviles F; Martinez JA; Mensa J; Gine E; Marcos MA; Soriano A
    Haematologica; 2022 Jul; 107(7):1731-1735. PubMed ID: 35295080
    [No Abstract]   [Full Text] [Related]  

  • 2. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside.
    Laracy JC; Kamboj M; Vardhana SA
    Curr Opin Infect Dis; 2022 Aug; 35(4):271-279. PubMed ID: 35849516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing patients with hematological malignancies during COVID-19 pandemic.
    Sahu KK; Cerny J
    Expert Rev Hematol; 2020 Aug; 13(8):787-793. PubMed ID: 32580592
    [No Abstract]   [Full Text] [Related]  

  • 4. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.
    Shah V; Ko Ko T; Zuckerman M; Vidler J; Sharif S; Mehra V; Gandhi S; Kuhnl A; Yallop D; Avenoso D; Rice C; Sanderson R; Sarma A; Marsh J; de Lavallade H; Krishnamurthy P; Patten P; Benjamin R; Potter V; Ceesay MM; Mufti GJ; Norton S; Pagliuca A; Galloway J; Kulasekararaj AG
    Br J Haematol; 2020 Sep; 190(5):e279-e282. PubMed ID: 32526039
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 in patients with hematologic malignancy.
    Langerbeins P; Hallek M
    Blood; 2022 Jul; 140(3):236-252. PubMed ID: 35544585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral treatment or mAbs for persistent SARS-COV-2 infection in patients with hematologic malignancies: A case series.
    Pérez-Catalán I; Gómez-Alfaro I; García-Muñoz S; Roig-Martí C; Rodríguez-Lozano N; Fabra-Juana S; Esteve-Gimeno MJ; Gascón-Buj A; Freiria-Alberte C; Clavel-Pia J; Torres-García M; Reig-Valero R; Ferrando-Piqueres R; Mateu-Campos L; Usó-Blasco J; Ramos-Rincón JM
    J Med Virol; 2023 Jun; 95(6):e28865. PubMed ID: 37314151
    [No Abstract]   [Full Text] [Related]  

  • 8. High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies.
    Niu A; Ning B; Socola F; Safah H; Reynolds T; Ibrahim M; Safa F; Alfonso T; Luk A; Mushatt DM; Hu T; Saba NS
    Leuk Res; 2021 Jul; 106():106582. PubMed ID: 33933714
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe COVID-19 in patients with hematological cancers presenting with viremia.
    Michot JM; Hueso T; Ibrahimi N; Pommeret F; Willekens C; Colomba E; Francis S; Bayle A; Cournède PH; Merad M; Foulon S; Albiges L; Gachot B; Barlesi F; Soria JC; Ribrag V; Griscelli F
    Ann Oncol; 2021 Oct; 32(10):1297-1300. PubMed ID: 34265373
    [No Abstract]   [Full Text] [Related]  

  • 10. SARS-CoV-2 infection and mortality in pediatric patients with hematological malignancies and solid tumors.
    Aguiar JEAT; Carvalho MAL; Viana SS; Martins-Filho PR; Cipolotti R
    Pediatr Hematol Oncol; 2023 May; 40(4):429-432. PubMed ID: 36094799
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India.
    Jain A; Nayak L; Kulkarni UP; Mehra N; Yanamandra U; Kayal S; Damodar S; John JM; Mehta P; Singh S; Munot P; Selvarajan S; Radhakrishnan V; Lad D; Kapoor R; Dubashi B; Bharath RS; Jain H; Jayachandran PK; Lakshmanan J; Mani T; Thorat J; Das S; Karunamurthy O; George B; Sengar M; Malhotra P
    Blood Cancer J; 2022 Jan; 12(1):2. PubMed ID: 34987161
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study.
    Rooney A; Bivona C; Liu B; Streeter D; Gong H; Khan Q
    J Hematol Oncol; 2022 May; 15(1):67. PubMed ID: 35597960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
    Ferrari S; Caprioli C; Weber A; Rambaldi A; Lussana F
    Leuk Lymphoma; 2021 Jun; 62(6):1490-1496. PubMed ID: 33461387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?
    Saad Albichr I; De Greef J; Van Den Neste E; Poiré X; Havelange V; Vekemans MC; Bailly S; Yombi JC; Mzougui S; Scohy A; Kabamba-Mukadi B
    Leuk Lymphoma; 2022 Mar; 63(3):743-746. PubMed ID: 34706604
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections.
    Moreno-Sanchez F; Gomez-Gomez B
    Curr Oncol Rep; 2022 Jul; 24(7):835-842. PubMed ID: 35316843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19.
    Tsiambas E; Papanikolaou V; Chrysovergis A; Mastronikolis N; Ragos V; Kavantzas N; Lazaris AC; Kyrodimos E
    Pathol Oncol Res; 2020 Oct; 26(4):2823-2825. PubMed ID: 32333199
    [No Abstract]   [Full Text] [Related]  

  • 18. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies.
    Modemann F; Niederwieser C; Weisel K; Bokemeyer C; Fiedler W; Ghandili S
    Leuk Lymphoma; 2022 Mar; 63(3):664-671. PubMed ID: 34668809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
    Cattaneo C; Cancelli V; Imberti L; Dobbs K; Sottini A; Pagani C; Belotti A; Re A; Anastasia A; Quaresima V; Tucci A; Chiorini JA; Su HC; Cohen JI; Burbelo PD; Rossi G; Notarangelo LD
    Blood Cancer J; 2021 Sep; 11(9):151. PubMed ID: 34521813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders.
    Glenthøj A; Jakobsen LH; Bjørn ME; Poulsen CB; Sengeløv H; Severinsen MT; Qvist K; Overgaard UM; Ahmad SA; Rewes A; Mølle I; Strandholdt CN; Kodahl AR; Ryg J; Brieghel C; Johansen IS; Kannik K; Jensen-Fangel S; Wiese L; Kirk O; Clausen MR; Helleberg M; Frederiksen H
    Acta Oncol; 2022 Apr; 61(4):500-504. PubMed ID: 35038967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.